Rituximab for the treatment of acquired antibodies to factor VIII
Background and Objectives Rituximab, a monoclonal chimeric antibody to the CD20 antigen, is an effective therapy for the treatment of non-Hodgkin’s lymphomas. Moreover, rituximab has also shown to be effective in various autoimmune diseases including spontaneous antibodies to factor VIII. The aim of...
Gardado en:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Ferrata Storti Foundation
2007-01-01
|
| Series: | Haematologica |
| Acceso en liña: | https://haematologica.org/article/view/4307 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|